PEP-Therapy Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
12
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$1.76M
- Investors
-
15
PEP-Therapy General Information
Description
Developer of peptides designed to offer targeted therapies for severe diseases, with an initial focus on oncology. The company's peptides offer intracellular drug delivery technology, cell-penetrating peptide capabilities, and targeted transport of therapeutic molecules to improve the delivery of therapeutic compounds, enabling pharmaceutical and biotechnology organizations to develop intracellular therapies with improved cellular access and therapeutic effectiveness.
Contact Information
Website
www.pep-therapy.comCorporate Office
- Pépinière Genopole Entreprises
- 4 rue Pierre Fontaine
- 91058 Evry Cedex
- France
Corporate Office
- Pépinière Genopole Entreprises
- 4 rue Pierre Fontaine
- 91058 Evry Cedex
- France
PEP-Therapy Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Later Stage VC | 01-Jan-2024 | $1.76M | Completed | Clinical Trials - General | ||
| 12. Secondary Transaction - Private | 01-Sep-2021 | Completed | Clinical Trials - General | |||
| 11. Later Stage VC (Series A) | 19-Jul-2021 | Completed | Clinical Trials - General | |||
| 10. Grant | 22-Apr-2021 | Completed | Clinical Trials - General | |||
| 9. Later Stage VC | 31-Oct-2020 | Completed | Pre-Clinical Trials | |||
| 8. Early Stage VC | 16-Nov-2017 | Completed | Pre-Clinical Trials | |||
| 7. Early Stage VC | Completed | Pre-Clinical Trials | ||||
| 6. Grant | 01-Jan-2016 | Completed | Pre-Clinical Trials | |||
| 5. Seed Round | 27-Apr-2015 | $1.4M | $1.4M | Completed | Pre-Clinical Trials | |
| 4. Accelerator/Incubator | Completed | Pre-Clinical Trials |
PEP-Therapy Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| P3 Shares | ||||||||
| P2 Shares | ||||||||
| O Shares | ||||||||
| P shares | ||||||||
| P shares | ||||||||
| Preference | 11,250 | $1.092273 | $116.51 | $116.51 | 1x | $116.51 | 8.83% | |
| Ordinary | 19,500 | $1.092273 | $72.82 | $72.82 | 1x | $72.82 | 15.31% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
PEP-Therapy Comparisons
Industry
Financing
Details
PEP-Therapy Competitors (32)
One of PEP-Therapy’s 32 competitors is BPS Bioscience, a Corporation company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BPS Bioscience | Corporation | San Diego, CA | ||||
| 4D pharma | Corporation | Leeds, United Kingdom | ||||
| Vir Biotechnology | Formerly VC-backed | San Francisco, CA | ||||
| Oncodesign Services | Private Equity-Backed | Dijon, France | ||||
| Sygnature Discovery | Private Equity-Backed | Nottingham, United Kingdom |
PEP-Therapy Patents
PEP-Therapy Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3086387-A1 | Cell penetrating peptides with improved internalization properties | Inactive | 22-Dec-2016 | ||
| EP-3559673-A1 | Cell penetrating peptides with improved internalization properties | Active | 22-Dec-2016 | ||
| EP-3559673-B1 | Cell penetrating peptides with improved internalization properties | Active | 22-Dec-2016 | ||
| US-10947276-B2 | Cell penetrating peptides with improved internalization properties | Active | 22-Dec-2016 | ||
| US-20190337985-A1 | Cell penetrating peptides with improved internalization properties | Active | 22-Dec-2016 | G01N33/68 |
PEP-Therapy Signals
PEP-Therapy Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CapHorn Invest | Venture Capital | Minority | ||
| Key Ventures | Venture Capital | Minority | ||
| Anaxago | Real Estate | Minority | ||
| Doorway Capital | PE/Buyout | Minority | ||
| i&i Prague | Accelerator/Incubator | Minority |
PEP-Therapy FAQs
-
When was PEP-Therapy founded?
PEP-Therapy was founded in 2014.
-
Where is PEP-Therapy headquartered?
PEP-Therapy is headquartered in Evry Cedex, France.
-
What is the size of PEP-Therapy?
PEP-Therapy has 12 total employees.
-
What industry is PEP-Therapy in?
PEP-Therapy’s primary industry is Drug Discovery.
-
Is PEP-Therapy a private or public company?
PEP-Therapy is a Private company.
-
What is the current valuation of PEP-Therapy?
The current valuation of PEP-Therapy is .
-
What is PEP-Therapy’s current revenue?
The current revenue for PEP-Therapy is .
-
How much funding has PEP-Therapy raised over time?
PEP-Therapy has raised $13.3M.
-
Who are PEP-Therapy’s investors?
CapHorn Invest, Key Ventures, Anaxago, Doorway Capital, and i&i Prague are 5 of 15 investors who have invested in PEP-Therapy.
-
Who are PEP-Therapy’s competitors?
BPS Bioscience, 4D pharma, Vir Biotechnology, Oncodesign Services, and Sygnature Discovery are some of the 32 competitors of PEP-Therapy.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process